View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
August 9, 2022

Filings buzz in pharma: 15% decrease in internet of things mentions in Q2 2022

We analyse companies' annual reports and other filings to spot topics receiving most attention.

By Data Journalism Team

Mentions of the internet of things within the filings of companies in the pharmaceutical industry fell 15% between the first and second quarters of 2022.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

In total, the frequency of sentences related to the internet of things between July 2021 and June 2022 was 400% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. The internet of things is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether the internet of things is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned the internet of things at least once in filings during the past twelve months - this was 21% compared to 8% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to the internet of things.

Of the 40 biggest employers in the pharmaceutical industry, Zydus Lifesciences was the company which referred to the internet of things the most between July 2021 and June 2022. GlobalData identified 13 internet of things-related sentences in the India-based company's filings - 0.2% of all sentences. Cipla mentioned the internet of things the second most - the issue was referred to in 0.15% of sentences in the company's filings. Other top employers with high internet of things mentions included Dr. Reddy's, ICON and IQVIA.

Across all pharmaceutical companies the filing published in the second quarter of 2022 which exhibited the greatest focus on the internet of things came from Inovio. Of the document's 1,031 sentences, six (0.6%) referred to the internet of things.

This analysis provides an approximate indication of which companies are focusing on the internet of things and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning the internet of things more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into the internet of things have been successes or failures.

GlobalData also categorises the internet of things mentions by a series of subthemes. Of these subthemes, the most commonly referred to topic in the second quarter of 2022 was 'connected car', which made up 35% of all internet of things subtheme mentions by pharmaceutical companies.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena